MetaVia Inc. — Director's Dealing 2020

Jan 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2019-12-30

Reporting Person: Oh Jeong Gyun (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-30	Common Stock	A	1817842	—	Acquired	1817842	Indirect
2019-12-30	Common Stock	A	240051	—	Acquired	240051	Indirect

Footnotes

F1: Received in connection with the closing of the merger of GR Merger Sub Inc., a wholly-owned subsidiary of the Issuer, with and into NeuroBo Therapeutics, Inc. (formerly NeuroBo Pharmaceuticals, Inc.) ("NeuroBo") on December 30, 2019, in exchange for (i) 1,000,000 shares of common stock of NeuroBo and (ii) 590,274 shares of common stock of NeuroBo issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by JK BioPharma Solutions, Inc.

F2: Mr. Oh is the President and Chief Executive Officer of JK BioPharma Solutions, Inc., and as such has voting and investment control over the shares held by JK BioPharma Solutions, Inc.

F3: Received in connection with the closing of the Merger in exchange for 210,000 shares of common stock of NeuroBo issued upon the conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by the spouse of Jeong Gyun Oh.

F4: In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock.

F5: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.